Related Experiment Video
Updated: Jul 9, 2026
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Correction of fragile X syndrome in mice
Gül Dölen1, Emily Osterweil, B S Shankaranarayana Rao
1Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Abstract:
Fragile X syndrome (FXS) is the most common form of heritable mental retardation and the leading identified cause of autism. FXS is caused by transcriptional silencing of the FMR1 gene that encodes the fragile X mental retardation protein (FMRP), but the pathogenesis of the disease is unknown. According to one proposal, many psychiatric and neurological symptoms of FXS result from unchecked activation of mGluR5, a metabotropic glutamate receptor. To test this idea we generated Fmr1 mutant mice with a 50% reduction in mGluR5 expression and studied a range of phenotypes with relevance to the human disorder. Our results demonstrate that mGluR5 contributes significantly to the pathogenesis of the disease, a finding that has significant therapeutic implications for fragile X and related developmental disorders.
Insights
Fragile X syndrome (FXS) is linked to FMR1 gene silencing. Reducing mGluR5 expression in mutant mice ameliorated FXS-related phenotypes, suggesting mGluR5 is a therapeutic target for FXS and related disorders.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- Fragile X syndrome (FXS) is a leading heritable cause of intellectual disability and a primary genetic cause of autism.
- The exact pathogenesis of FXS, stemming from FMR1 gene silencing and lack of FMRP, remains unclear.
- A leading hypothesis suggests that overactive metabotropic glutamate receptor 5 (mGluR5) contributes to FXS symptoms.
Purpose of the Study:
- To investigate the role of mGluR5 in the pathogenesis of Fragile X syndrome.
- To determine if reducing mGluR5 expression can alleviate FXS-related phenotypes.
Main Methods:
- Generation of Fmr1 mutant mice with a 50% reduction in mGluR5 expression.
- Comprehensive assessment of various phenotypes in these mice relevant to human FXS.
Main Results:
- Fmr1 mutant mice with reduced mGluR5 expression exhibited amelioration of key disease-related phenotypes.
- These findings provide direct evidence for mGluR5's significant contribution to FXS pathogenesis.
Conclusions:
- Metabotropic glutamate receptor 5 plays a critical role in the development of Fragile X syndrome.
- Targeting mGluR5 presents a promising therapeutic strategy for Fragile X syndrome and associated neurodevelopmental disorders.
